MET and colorectal carcinoma: Co-occurring CCNE1 gene amplification was observed in 66.6% (4/6) of GC while potentially actionable receptor tyrosine kinase gene (EGFR, MET, and FGFR1) copy number gains were observed in 100% (5/5) CRC patient samples.